Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 9;28(1):332–345. doi: 10.3390/curroncol28010037

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Management strategies for patients with CLL. (A) Treatment pattern of OTT scenario, with evolving therapeutic options over time. (B) Treatment pattern of CIT scenario, which continues the use of CIT as the standard of care through time. For the base-case analysis, the most widely used therapy was selected when more than one therapy was considered available for patients in the same condition (shown in bold). B, bendamustine; BR, bendamustine and rituximab; CIT, chemoimmunotherapy; Clb, chlorambucil; Clb+R, chlorambucil and rituximab; CLL, chronic lymphocytic leukemia; del(17p), deletion at chromosome 17p targeting the TP53 gene; F, fludarabine; FCR, fludarabine, cyclophosphamide and rituximab; FR, fludarabine and rituximab; GClb, obinutuzumab and chlorambucil; IGHV, immunoglobulin heavy-chain variable; OTT, oral targeted therapy; R, rituximab.

Management strategies for patients with CLL. (A) Treatment pattern of OTT scenario, with evolving therapeutic options over time. (B) Treatment pattern of CIT scenario, which continues the use of CIT as the standard of care through time. For the base-case analysis, the most widely used therapy was selected when more than one therapy was considered available for patients in the same condition (shown in bold). B, bendamustine; BR, bendamustine and rituximab; CIT, chemoimmunotherapy; Clb, chlorambucil; Clb+R, chlorambucil and rituximab; CLL, chronic lymphocytic leukemia; del(17p), deletion at chromosome 17p targeting the TP53 gene; F, fludarabine; FCR, fludarabine, cyclophosphamide and rituximab; FR, fludarabine and rituximab; GClb, obinutuzumab and chlorambucil; IGHV, immunoglobulin heavy-chain variable; OTT, oral targeted therapy; R, rituximab.